PubMed
Melanotan II and its molecular mechanisms
Dorr RT, Dawson BV, Hadley ME, et al. Life Sci. 2009
Compare
Melanotan II vs Selank
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Melanotan II
46 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Libido
142
Mood
141
Appetite
73
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Fatigue
2
Nausea
2
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.01–2 mg
0.01–0.025 mg
1
0.05–0.1 mg
1
0.1–0.2 mg
7
0.2–0.4 mg
49
0.4–0.6 mg
23
0.6–1 mg
33
1–2 mg
28
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 94% said they felt similar to their last entry, 6% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 50 days · Based on 32 repeat reporters
Selank
57 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Mood
184
Recovery
184
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
94
Fatigue
85
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
3
0.2–0.4 mg
96
0.4–0.6 mg
76
0.6–1 mg
5
1–2 mg
2
5+ mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
How repeat users are trending
Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 54 days · Based on 35 repeat reporters
Sources (9)
Published sources linked on the Melanotan II and Selank wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs
Mestria S, Odoardi S, Frison G, et al. Drug testing and analysis. 2021
- Wiki study page →Source
PubMed
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis
Nelson ME, Bryant SM, Aks SE. Clinical toxicology (Philadelphia, Pa.). 2012
- Wiki study page →Source
PubMed
Selank and short peptides regulate expression of inflammatory genes
Ershov FI, Uchakin PN, Ershova OV. Bull Exp Biol Med. 2017
- Wiki study page →Source
PubMed
Selank, a tuftsin analogue, demonstrates anxiolytic activity
Seredenin SB, Kozlovskaya MM. Bull Exp Biol Med. 2008
- Wiki study page →Source
PubMed
Selank modulates immune system activity
Ershov FI, Uchakin PN. Bull Exp Biol Med. 2010
- Wiki study page →Source
ClinicalTrials.gov
Selank studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Functional Connectomic Approach to Studying Selank and Semax Effects
Panikratova YR, Lebedeva IS, Sokolov OY, et al. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020
- Wiki study page →Source
PubMed
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
Konstantinopolsky MA, Chernyakova IV, Kolik LG. Bulletin of experimental biology and medicine. 2022